Bleomycin Sulfate

目录号:S1214 别名: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate硫酸博来霉素是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。

规格 价格 库存 购买数量  
RMB 1410.29 现货
RMB 5474.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献6篇:

客户使用该产品的1个实验数据:

  • AACR 2011 Bleomycin Sulfate purchased from Selleck.

质量管理及产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Bleomycin Sulfate硫酸博来霉素是一种糖肽类抗生素,也是一种鳞状细胞癌(SCC)抗癌剂,在UT-SCC-19A细胞中IC50为4 nM。
体外研究

UT-SCC-12A和 UT-SCC-12B均对Bleomycin sulfate耐药,IC50分别为14.2 nM 和13 nM。[1]肺泡巨噬细胞与0.01 μg/mL到1μg /mL Bleomycin sulfate培养18小时显著比巨噬细胞单独培养分泌更多的成纤维细胞生长因子。Bleomycin sulfate刺激的巨噬细胞持续产生大量成纤维细胞生长因子,即使在移去Bleomycin sulfate,用新鲜培养基(不含Bleomycin sulfate)取代之后,该作用依然存在。Bleomycin sulfate刺激肺泡巨噬细胞导致的纤维素生长因子分泌被环己酰亚胺,和5-脂氧合酶抑制剂NDGA(去甲二氢愈创木酸)和BW755c抑制,表明其不仅需要蛋白质合成,也需要花生四烯酸代谢的5-脂氧合酶途径活性完全表达。[2] Bleomycin sulfate (400 µg/mL)培养24小时,降低NTera-2细胞的活性,增加caspase-3,-8和-9的活性,增加Bax和细胞质细胞色素C水平,并降低Bcl-2水平。[3]对于不稳定性畸变,Bleomycin sulfate对ADIPO-P2细胞的致染色体断裂作用在处理后至少持续10天。此外,暴露于Bleomycin sulfate的细胞处理10天后,端粒融合体的外观表明Bleomycin sulfate能够诱导延迟的端粒失稳。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NUnEdYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LtZ|DjiJNzMECwJO69dQ>? MYmyOEBpyqB? NYG4OWVocW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NWLiZXpwOjZyOEi3NVE>
POLK WT NYnjepM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP MoLiNlYxOzF2MEC=
POLK KO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6wTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= MUSyOlA{OTRyMB?=
POLK CD M1TQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fucWlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN NGPMZW0zPjB|MUSwNC=>
RLE/Abca3 MmHLSpVv[3Srb36gRZN{[Xl? Mn20NE41yqEQvF2= NV62Z|Y5OTR2wrDo NWGyfXJKcW6mdXPld{BiKG2xcoDoc4xw\2mlYXygZ4hidmenIH\yc40h\XCrdHjlcIlidC2uaXvlJI1wenCqb3zv[5khfG9iYTD3bYRmNCC|cILlZYQud3W2IH3vdpBpd2yxZ4pCpC=> M2fOPFI2PzZyNUO4
PMCs M4LVd2Z2dmO2aX;uJGF{e2G7 M{HsdlAvOeLCk{NCpO69\y:vbB?= M2nGUFI1yqCq MYDjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnPy[YF{\SCrbjD0bIUheHKxdHXpckBt\X[nbDDv[kBkd2yuYXflck1KyqB? NIT1OHgzPTV7NU[0Ni=>
PMCs M3:xeWZ2dmO2aX;uJGF{e2G7 NVrNZ21ZOC5{wrFOwIcwdWx? Mo[5NlTjiJN5MtMgbC=> NI\EfVlqdmS3Y3XzJIlv[3KnYYPld{BqdiC4aX3lcpRqdiCjbnSg{tEuW02DIIDyc5RmcW5? MXKyOVU6PTZ2Mh?=
PMCs M3HvSGZ2dmO2aX;uJGF{e2G7 M4i3N|AvOsLizsznM41t MVy3NkBp M1HWVolv\HWlZYOg[IVkemWjc3XzJIlvKGO7dH;r[ZJifGmwLUigZY5lKEVvY3HkbIVzcW5icILveIVqdg>? MofsNlU2QTV4NEK=
PMCs NXPyNJpPTnWwY4Tpc44hSXO|YYm= MXKwMlLDqM7:Zz;tcC=> MVmxNk8zPC92ODDo MWfpcoNz\WG|ZYOgZ4VtdCCvaXfyZZRqd25? M3u0SVI2PTl3NkSy
IMR-32 M1mwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\GO|Y4NjYkiKKxNlAhyrWpL33s NYXhcXdPOTMkiKK0PEBp NYjPO5pLUUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= NGTE[oYzPTV|NkO0OS=>
HT1080 M1K3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxJO69VQ>? M1q5NlI1KGkEoB?= NGXqZXFt\WGmczD0c{BiKEd{L12g[IVt[Xl? M3PydVI2PTF6OU[x
HT1080 M3XCXGZ2dmO2aX;uJGF{e2G7 Mkj4NUDPxE1? NIPQcnozPCCqwrC= NGr3W5BqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl M1;JN|I2PTF6OU[x
HDFn NUOxeYJuS3m2b4TvfIlkcXS7IFHzd4F6 MXm3NkBp NXzZZoJJUUN3ME25MlMyLcLi Mlf0NlUzPzZ5OUK=
THP-1 NFXx[phEgXSxdH;4bYNqfHliQYPzZZk> MnHJO|IhcA>? M2TNPGlEPTB;ND63O{U> MV2yOVI4Pjd7Mh?=
HT-29 MXPDfZRwfG:6aXPpeJkhSXO|YYm= NF7HV4U4OiCq MonpTWM2OD1zMT60PUU> M3PpVVI2Ojd4N{my
HCT116  NW\LZY9{S3m2b4TvfIlkcXS7IFHzd4F6 MmLvO|IhcA>? NXviNJN7UUN3ME2xNU4{PCV? M3LEdFI2Ojd4N{my
A431 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qxblUxNTJyMDDJWS=> NY\1OnNDPDkkgJno MULpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MkKyNlUyODF{OUm=
T24 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6yOVAuOjByIFnV MkG4OFjjiImq M4e4colvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NV7WfIF1OjVzMEGyPVk>
AY-27  NEHmfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\IfGtiPTBvMkCwJGlW NF7iUFc1QOLCiXi= MkW0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NVnFbpVGOjVzMEGyPVk>
A549 M4DBS2Z2dmO2aX;uJGF{e2G7 NV\JRplYOSEEtXevcWzDqA>? M3n3PVAuPDhiaB?= MWrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> NYLib3lIOjR7NkO2N|U>
MLE12 MXrGeY5kfGmxbjDBd5NigQ>? MVqxJOK2\y:vTNMg NGP3NYoxNTR6IHi= M1LJNolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[uKhV1CQwrDtVm5C MXuyOFk3OzZ|NR?=
Jurkat MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37yVlIx6oDLzszt MUKyOQKBkWkEoB?= M{\mdYFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm NY\BOY9[OjR7MU[4PVM>
HeLa  NXvEUXI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXlSmlKUUN3ME2xNE4zyqEQvF2= MU[yOFc{OjN7Nx?=
C18-4 NGjtZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfNV2UxNTFyMDFOwG0> NEPTXmRqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NFXLdXYzPDV5MUm4Ni=>
BMG-1  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy0NE85OMLizsznM40> M1H5UlPDqGh? MVvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NISyUXkzOzlyNkeyOi=>
A459 M1vGZmFxd3C2b4Ppd{BCe3OjeR?= NFHvbVkyOCCvVR?= MVm0PEBp MYXpcoR2[2W|IHHwc5B1d3Orcx?= NITMOZYzOzlyMke2Oi=>
MOCK M{GybWFxd3C2b4Ppd{BCe3OjeR?= MYqxNEBuXQ>? MVG0PEBp NWXZVotFcW6mdXPld{BieG:ydH;zbZM> NEPDWVEzOzlyMke2Oi=>
MMP1 MkPZRZBweHSxc3nzJGF{e2G7 MnH3NVAhdVV? NGfSR|k1QCCq MUDpcoR2[2W|IHHwc5B1d3Orcx?= MlrzNlM6ODJ5Nk[=
A549 NHjtc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlywNlAxKM7:TR?= MonZNlQhcMLi M2XneYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MUCyN|gxPTd7Mx?=
HCT-116 NW\nV21WSXCxcITvd4l{KEG|c3H5 NUnWelA{Oy95LkWvNVUh|rypL33s MoTvOFghcA>? MUTy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u M4\mZVI{PzB6Nk[4
HeLa MlHpRZBweHSxc3nzJGF{e2G7 NEPVeVk{NzdwNT:xOUDPxGdxbXy= NHTWTGY1QCCq MVLy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u NGLhdJMzOzdyOE[2PC=>
HCT116 M12xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMVExOCEQvHevcYw> MX20PEBp NV7wOI4ycW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NVy4TZhmOjN3MUiyNFE>
NCM460 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3hNE0yODBizsznM41t MVS0PEBp Mn[3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MlrMNlM2OTh{MEG=
NT2  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WwS|I1KGkEoB?= MmqxUGQ2OD12MEFihKnDvWdxbXy= MX6yN|M5PjR{MB?=
NT2  NUL0Roh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTXVGk6PDhiaB?= NEjGcoFNTDVyPUGwNEDDvWdxbXy= NGTWV5gzOzN6NkSyNC=>
NT2  M{LseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLleI85PzJiaB?= M1;NNWxFPTB;MkFihKnDvWdxbXy= MnHYNlM{QDZ2MkC=
NT2  MUTBdI9xfG:|aYOgRZN{[Xl? Mly0OFAx6oDLwsXnM41t NULYenBFOjRiaNMg MUfpcoR2[2W|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> M3nWSFI{Ozh4NEKw
NTera-2 MVTGeY5kfGmxbjDBd5NigQ>? NEnGd4IyOjBizsznM41t M1;IZlczKGh? NHTkOnZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> MUCyNlgzPTN3NR?=
NCCIT NXTzN4F7TnWwY4Tpc44hSXO|YYm= NHrKb5AyOjBizsznM41t NYiwTpBbPzJiaB?= M1y4V5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz NGTqdogzOjh{NUO1OS=>
NTera-2 M1;F[mZ2dmO2aX;uJGF{e2G7 NF3QXlcyOjBizsznM41t MkT3O|IhcA>? NEHPUWR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MV[yNlgzPTN3NR?=
NCCIT M{PHe2Z2dmO2aX;uJGF{e2G7 NX6zeohoOTJyIN88[{9udA>? M2XIe|czKGh? NGW1VnR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> Mnj2NlI5OjV|NUW=
NCCIT MnrFSpVv[3Srb36gRZN{[Xl? MoLvNVIxKM7:Zz;tcC=> NEDPO4Q4OiCq MoPwd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= MWiyNlgzPTN3NR?=
NTera-2 MofSSpVv[3Srb36gRZN{[Xl? NWrHNlduOTJyIN88[{9udA>? MX:3NkBp NXLNcnRYe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? M4HiWVIzQDJ3M{W1
NCCIT NXrTWZp4TnWwY4Tpc44hSXO|YYm= M1u2eFEzOCEQvHevcYw> NIrRWWE4OiCq MY\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> MWWyNlgzPTN3NR?=
NTera-2 Mkm2SpVv[3Srb36gRZN{[Xl? MmPPNVIxKM7:Zz;tcC=> M4DPVVczKGh? M{PQS5Nq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NXKyRpBoOjJ6MkWzOVU>
NCCIT NGPLWplHfW6ldHnvckBCe3OjeR?= MoDCNVIxKM7:Zz;tcC=> MUO3NkBp MV;zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCOUF:gcIV3\Wy| NVHq[oQzOjJ6MkWzOVU>
MDA-MB-468 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\iZlDjiJN{MEFCpO69\y:vTB?= MUeyOEBp NY\4UmJwcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M1vGVFIzQDF7MUm2
231-H2N M1zET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi4[Gkx6oDVMkCwxsDPxGdxbVy= M3vPcFI1KGh? MmPnbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MkT3NlI5OTlzOU[=
A549  NU\4OG1MTnWwY4Tpc44hSXO|YYm= MWOyNFAwPDByIN88US=> MYLy[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= NFzxOmYzOjd5M{[5Oy=>
A549  Ml3XSpVv[3Srb36gRZN{[Xl? M{jPO|AuPDByIN88US=> M4\h[lIuPDhiaB?= MoX3Z4F2e2W|IH3vdoUhdXSGTlGgeIhidiCwRF7BJIRidWGpZR?= NYnqNZViOjJ5N{O2PVc>
A549  NVPndW1jTnWwY4Tpc44hSXO|YYm= NFzzPJcyODBizszNxsA> MWOw5qCUPDhiaB?= NXXM[Y5l[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MW[yNlc4OzZ7Nx?=
A549  M1;jWmZ2dmO2aX;uJGF{e2G7 MV[xNFAh|ryPwrC= M{nnSVDjiJN2ODDo MVPjZZV{\XNiUFvENUBkdGWjdnHn[S=> M2LMe|IzPzd|Nkm3
A549  MoHuSpVv[3Srb36gRZN{[Xl? M{\S[lExOCEQvF5CpC=> M4LSRlDjiJN2ODDo NWXaOmts[2G3c3XzJI1qfG:laH;u[JJq[WxibH;jZYxqgmG2aX;uJI9nKEKjeB?= NUDXV3Y{OjJ5N{O2PVc>
A549  NX;Pcm9CTnWwY4Tpc44hSXO|YYm= NUTaNXJiOTByIN88UeKh MlfFNQKBmzR6IHi= MoTs[IVkemWjc3XzJG1OWCCjbnSgRXRRKGyndnXsdy=> MUKyNlc4OzZ7Nx?=
MCF-7/Her-18  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnkPJExNjR{LUG3NFAh|rypL33M NHvYdGwzPCCq NV25RnN6cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NIS5UVkzOjZ{MUSwOC=>
MCF-7 NYnBS2RYWESWL2DDTUBVemWjdH3lcpQ> MV6wMlI2KM7:Zz;tcE4> MWCxMVQhcA>? NYTMWHVRe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? NIi2UlYzOjV7MUK4OC=>
MDA-MB-231 M2r0V3BFXC:SQ1mgWJJm[XSvZX70 MVKwMlI2KM7:Zz;tcE4> M3HwOlEuPCCq NYrnRnRne2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MXyyNlU6OTJ6NB?=
MDA-MB-235  NFjwcVBRTFRxUFPJJHRz\WG2bXXueC=> MmT4NE4zPSEQvHevcYwv MkTQNU01KGh? M4XTZ5Npd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> MYqyNlU6OTJ6NB?=
MCF-7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDuNE0zKM7:Zz;tcE4> NHvldYIzPC92ODDo MUTFR|UxRTFwMjFOwIcwdUx? NGTOb|UzOjV7MUK4OC=>
NCCIT  M4CxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\CNlDjiJNzNEFCpO69\y:vbB?= MonZO|IhcA>? MnnTUGQ2OD1zMkFCpO69\y:vbNMg MYCyNlU3OjF4MB?=
NCCIT  NUK0WGxSTnWwY4Tpc44hSXO|YYm= MYK3NkBp Mn\xd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NVruR|VrOjJ3NkKxOlA>
NCCIT  M2DifGZ2dmO2aX;uJGF{e2G7 M4PFbFczKGh? M{fXZpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvODDhZ5Rqfmm2edMg NFHoWWczOjV4MkG2NC=>
NCCIT  NUjUZZh5TnWwY4Tpc44hSXO|YYm= NIXrUYg4OiCq M17aUpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg NVnsXGJuOjJ3NkKxOlA>
NCCIT  MoLZSpVv[3Srb36gRZN{[Xl? MmTxO|IhcA>? MkP3d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MoLyNlI2PjJzNkC=
NCCIT  M3Pmc2Z2dmO2aX;uJGF{e2G7 NFzRPG84OiCq NVTxXJk5e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKEKlbD2yJINwdnSnboS= M1rk[FIzPTZ{MU[w
NCCIT  MlToSpVv[3Srb36gRZN{[Xl? NHn6U4M4OiCq MkTRd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGN6fC2lIHzleoVt MYmyNlU3OjF4MB?=
HeLa NVvucHN1TnWwY4Tpc44hSXO|YYm= MYOzNE84OCEQvHevcYw> MWWyOOKhcA>? NGTXUJFqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NF\lSnQzOjR6N{mzOy=>
MCF-7  NVzReHg2TnWwY4Tpc44hSXO|YYm= NHH4UJY{OC95MDFOwIcwdWx? NUPxVVZ4OjUEoHi= MV\pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NHuxU2gzOjR6N{mzOy=>
HeLa MlvRR5l1d3SxeHnjbZR6KEG|c3H5 NHS3WIQ{OC95MDFOwIcwdWx? M1fjc|I1yqCq MX7pcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? MUCyNlQ5Pzl|Nx?=
MCF-7  NI\RZZpEgXSxdH;4bYNqfHliQYPzZZk> NVjtRZZWOzBxN{Cg{txoN22u MWqyOOKhcA>? M{HaVIlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= MofnNlI1QDd7M{e=
NT2 M4nFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxNFAuPjBywrFOwIcwdWx? MmjKNlQhcA>? NEXRcHRKSzVyPUSwNEDDvWdxbXy= MnSzNlI1Pjl7NUK=
NT2 MX3GeY5kfGmxbjDBd5NigQ>? M1q4PFQxOMLizsznM41t MYSyOEBp MUnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> MlHlNlI1Pjl7NUK=
NT2 NXT6WYZzTnWwY4Tpc44hSXO|YYm= MnvwOFAxyqEQvHevcYw> MmnRNlQhcA>? M3HCfZNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= NGr0WJkzOjR4OUm1Ni=>
NT2 MYLGeY5kfGmxbjDBd5NigQ>? NX\vflNDPDBywrFOwIcwdWx? M1:4c|I1KGh? MmDUd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQnPsMVIhdGW4ZXy= Mn\pNlI1Pjl7NUK=
CHO MkX4SpVv[3Srb36gRZN{[Xl? M{GwNVIvPcLizsznM41t NG\UcXgyQCCqL{[g[C=> NHfr[ZZqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= MVKyNlI{ODF7NR?=
Jurkat MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfMNE0yODEEoN88[{9udA>? NWrBemhTOjRiaB?= MYDhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> NVjHWXZJOjJ{MkOzN|I>
Jurkat MXjGeY5kfGmxbjDBd5NigQ>? MY[zNOKh|rypL33s MoPTNlQhcA>? NEfre2pqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIHP5Z4xqdnNiREOsJGEh[W6mIFKx MmDLNlIzOjN|M{K=
Jurkat MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O1Z|AuOTBywrFOwIcwdWx? MoPqNlQhcA>? NELwWphqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= NGK1S3IzOjJ{M{OzNi=>
Jurkat NXf3O|FJTnWwY4Tpc44hSXO|YYm= NWS4[JQ2OzEEoN88[{9udA>? MkDPNlQhcA>? MnTDbY5kemWjc3XzJJRp\SCnZn\lZ5Qhd2ZicInjcollcW:wZTDvckBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IH;mJIhqe3SxbnWgTFJCNlh? NHvTTlIzOjJ{M{OzNi=>
U2OS EGFPnls MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPlNE0zyqEQvHevcYw> M{XNcFI1KGh? Mlr4bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NFrqR3QzOThzMUCwOy=>
U2OS KuEnls NEHjd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[wMVLDqM7:Zz;tcC=> MYeyOEBp MoPQbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NInSNoEzOThzMUCwOy=>
MCF-7 M13nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVewMVQxOCEQvF2= M1v1cFczKGh? MnrmUGM2OD1zNUGuPOKh|ryP Ml;CNlE4ODN{OUG=
MCF-7/Adr  M3XoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljBNE01ODBizszN MljuO|IhcA>? MXzMR|UxRTV6LkZCpO69VcLi NIXKS4YzOTdyM{K5NS=>
WI-38 MYrGeY5kfGmxbjDBd5NigQ>? M1XaXVAwPDBxOEFihKnPxGdxbX|CpC=> NE[weG8{KGh? NIPRVYhqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NXz2coRiOjF3OUm2NVI>
hBMSC MlfYSpVv[3Srb36gRZN{[Xl? MVywM|QxNzhy4pEJ{txoN22uwrC= MlrWN{Bp M{j6cIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MX6yNVU6QTZzMh?=
NCI-H23 Mln1SpVv[3Srb36gRZN{[Xl? MVuwM|QxNzhy4pEJ{txoN22uwrC= MkC2N{Bp M3zYfolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NUXMc5VpOjF3OUm2NVI>
A-549 MXXGeY5kfGmxbjDBd5NigQ>? MXuwM|QxNzhy4pEJ{txoN22uwrC= MnnnN{Bp NETqTFZqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NW\PVVFiOjF3OUm2NVI>
PBL  NVXLdnFsTnWwY4Tpc44hSXO|YYm= M4D0[lAwPDBxOEFihKnPxGdxbX|CpC=> NEfleGU{KGh? MlLzbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MVuyNVU6QTZzMh?=
pol β −/− M1rpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJPFAvOjVvMkCwxsDPxGdxbXy= NWOzVJlYOjUEoHi= Mo\L[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh MlfXNlEzPTF7NES=
pol β +/+ M1T2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOwMlI2NTJyMNMg{txoN22u MYqyOOKhcA>? M{DKOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bZRpKGmwY4LlZZNqdmdiY3;uZ4VvfHKjdHnvcpPDqA>? M2jGSVIyOjVzOUS0
pol β −/− M1fzOmZ2dmO2aX;uJGF{e2G7 M{XvflAuOi53IN88[{9udA>? NILXelgzKGh? MV\jZZV{\XNiRF7BJIRidWGpZR?= M1y0PFIyOjVzOUS0
pol β +/+ MXHGeY5kfGmxbjDBd5NigQ>? NFrBfnQxNTJwNTFOwIcwdWx? M3\RUlIhcA>? M4DjNoNifXOnczDEUmEh\GGvYXfl NULIV4pSOjF{NUG5OFQ>
pol β −/− NWG1SWtwTnWwY4Tpc44hSXO|YYm= MlXDNE02KM7:Zz;tcC=> NUS4bnJqPDhiaB?= M4LPW4NifXOnczDtbYNzd263Y3zleZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MnXDNlEzPTF7NES=
pol β +/+ MlHqSpVv[3Srb36gRZN{[Xl? MnPyNE02KM7:Zz;tcC=> MmruOFghcA>? NHLkNZdk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MYWyNVI2OTl2NB?=
TK6  NYexSYplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqyOU0yPTBizsznM41t MkTMPVYhcA>? MlLUbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MlqyNlExQDF2OEe=
TK6  sLUC+Apn1 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmyOU0yPTBizsznM41t M{jB[Fk3KGh? NXfsOG9EcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NWH3XJpXOjFyOEG0PFc>
TK6 sAPE1+Apn1 NILue25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELWSlkzPS1zNUCg{txoN22u MofTPVYhcA>? MUPzbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? Mn:yNlExQDF2OEe=
HCT116 NXq1[3R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GwelI2NTF3MDFOwIcwdWx? M3L1Z|k3KGh? MWPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NUDVdmNbOjFyOEG0PFc>
HCT116 sLUC+Apn1 NEP0dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvMVHZsOjVvMUWwJO69\y:vbB?= NVX4Ung6QTZiaB?= MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NUXveGN7OjFyOEG0PFc>
HCT116 sAPE1+Apn1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3N|RpOjVvMUWwJO69\y:vbB?= M2C0UFk3KGh? MX3zbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4Uh\GWyZX7k[Y51dHl? MkG5NlExQDF2OEe=

... Click to View More Cell Line Experimental Data

体内研究 Bleomycin sulfate处理后第7天,NOX-/- 的BALf中CD45+细胞是WT的1.7倍多,其中57%为Mf,第21天,在WT中减少到67%,在NOX-/-中减少到83%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[4]
+ 展开
  • Cell lines: ADIPO-P2 细胞
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30分钟
  • Method: ADIPO-P2细胞在D-MEM高葡萄糖培养基中生长,用20%胎牛血清,青霉素(100 U/mL) 和链霉素 (100 μg/mL)增补,在37 °C 和5% CO2大气环境中培养。细胞在包含1.5×105 cells/mL的TC25 Corning培养瓶中单层培养。对于每个实验,建立两个培养瓶,一个用于对照组,一个用于处理培养。在对数生长期,ADIPO-P2细胞用2.5 μg/mL Bleomycin sulfate以30分钟脉冲处理。建立平行对照组,不暴露于Bleomycin sulfate。暴露时间和Bleomycin sulfate浓度根据先前实验室中进行的Bleomycin sulfate处理哺乳动物细胞的研究进行选择。Bleomycin sulfate脉冲处理结束时,细胞用Hank's平衡盐溶液清洗两次,并保存在新鲜培养基中直到采集。处理后5个传代培养期间,将细胞持续保持在培养基中。当培养基中融合(培养基中大约4×105 cells/mL)时,进行传代培养。为估计细胞生长,传代培养时,细胞通过胰蛋白酶化收集,每等份大约200 μL,用0.4%台盼蓝着色,测定活细胞数量。随后细胞悬浮在新鲜培养基中,重新分配到包含1×105 cells/mL的新培养瓶中继续生长。将剩余的细胞丢弃或置于另外的培养瓶中进行细胞遗传学分析,这在处理结束后18小时或第10天进行。为分析染色体突变,培养的最后3小时将colchicine (0.1 μg/mL)加入到细胞培养基。染色体的制备根据标准程序进行。采集后,将细胞低渗震动,固定在甲醇:乙酸(3:1)中,涂布在载玻片上,进行PNA-FISH。进行两个独立的实验。
    (Only for Reference)
动物实验:[7]
+ 展开
  • Animal Models: CD-1小鼠
  • Formulation: 生理盐水
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: 鞘内注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 1512.62
化学式

C55H85N17O25S4

CAS号 9041-93-4
稳定性 powder
in solvent
别名 NSC125066

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03596918 Recruiting AIDS-Related Kaposi Sarcoma|Human Immunodeficiency Virus 1 Positive AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California Los Angeles October 10 2018 Phase 1
NCT02166463 Recruiting Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma National Cancer Institute (NCI) March 16 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children''s Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01132807 Completed Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 8 2010 Phase 2
NCT01026220 Completed Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Children''s Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate价格 | Bleomycin Sulfate DMSO溶解度 | 采购Bleomycin Sulfate | Bleomycin Sulfate生产 | Bleomycin Sulfate 小鼠 | Bleomycin Sulfate化学结构 | Bleomycin Sulfate分子量 | Bleomycin Sulfate molecular weight | Bleomycin Sulfate说明书 | Bleomycin Sulfate供应商 | Bleomycin Sulfate体内 | Bleomycin Sulfate细胞系 | Bleomycin Sulfate浓度 | Bleomycin Sulfate nmr | Bleomycin Sulfate核磁 | Bleomycin Sulfate半数抑制浓度 | Bleomycin Sulfate体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID